Please assess the completion status of the following clinical trial:

Trial Title: Effect of Omega 3 as an Immunomodulator Adjunct to Periodontal Debridement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients ≥ 18 years.~* Patients American Society of Anesthesiologists (ASA) I or ASA II compatible with local anesthesia procedures.~* Present at least 10 natural teeth, excluding semi-erupted third molars.~* Present at least 6 sites with a probing depth (PD) ≥ 5mm and clinical attachment loss (CAL) ≥ 4mm~Exclusion Criteria:~* Patients with hemostasis disorders.~* Patients who use any medication associated with gingival disorders such as: Anticonvulsants (Phenytoin), Calcium channel blockers (Nifedipine), Immunosuppressive drugs (Cyclosporins).~* Patients with systemic diseases that affect the immunoinflammatory response.~* Patients under treatment with antacids on a regular basis due to chronic gastritis and / or self-medication with antacids.~* Patients under treatment with drugs such as: warfarin, digoxin and acetylsalicylic acid.~* Previous history of allergy to local anesthetics.~* Patients presenting orthodontic appliances.~* Patients who have received antibiotic treatment in the last 3 months.~* Patients who have received periodontal treatment.~* Pregnancy.~* Carriers of valvular prostheses or failures in heart valves, with endocarditis risk.~* Patients who are physically and intellectually incapacitated to participate, according to chilean law number 20,584, title II, paragraph 8, article 28.~* Heavy smoking patients, which is smoking more than 10 cigarettes per day.~* Patients allergic to Omega 3 or seafood or its derivatives: fish, shellfish, algae, etc.~* Patients with lactose intolerance.

- Gender: ALL
- Minimum Age: 39 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Periodontal treatment, lactose tab (Type: PLACEBO_COMPARATOR): Periodontal treatment (scaling and root planning) and two tablets containing lactose once a day for 90 days immediately after the scaling and root planning.
- Periodontal treatment, Omega 3 (Type: EXPERIMENTAL): Periodontal treatment (scaling and root planning) and two tablets containing 1g of Omega 3 once a day for 90 days immediately after the scaling and root planning.

Based on this trial design, predict the completion outcome and termination type (if applicable).